ATI RN
WGU Pathophysiology Final Exam
1. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary therapeutic action of this medication?
- A. It stimulates the formation of new bone.
- B. It decreases bone resorption and increases bone density.
- C. It increases calcium absorption in the intestines.
- D. It increases the excretion of calcium through the kidneys.
Correct answer: B
Rationale: The correct answer is B. Raloxifene works by decreasing bone resorption and increasing bone density, which helps in the prevention and treatment of osteoporosis. Choice A is incorrect as raloxifene does not directly stimulate the formation of new bone. Choice C is incorrect because raloxifene does not primarily affect calcium absorption in the intestines. Choice D is incorrect as raloxifene does not increase the excretion of calcium through the kidneys.
2. A woman is complaining that she feels like the room is spinning even though she is not moving. Which of the following is characteristic of benign positional vertigo?
- A. It usually occurs with a headache.
- B. Pupillary changes are common.
- C. It is usually triggered when the patient bends forward.
- D. Nystagmus continues even when the eyes fixate on an object.
Correct answer: C
Rationale: The correct answer is C: 'It is usually triggered when the patient bends forward.' Benign positional vertigo is often triggered by changes in head position, such as bending forward. Choices A, B, and D are incorrect. A is incorrect because benign positional vertigo is not typically associated with headaches. B is incorrect because pupillary changes are not a common feature of benign positional vertigo. D is incorrect because nystagmus in benign positional vertigo usually stops when the eyes fixate on an object.
3. A patient with a history of breast cancer is being prescribed tamoxifen (Nolvadex). The nurse should educate the patient about what potential side effect of this medication?
- A. Increased risk of venous thromboembolism
- B. Increased risk of hot flashes
- C. Increased risk of cataracts
- D. Increased risk of bone fractures
Correct answer: A
Rationale: The correct answer is A: Increased risk of venous thromboembolism. Tamoxifen is known to increase the risk of venous thromboembolism, a serious side effect. Patients should be educated about the signs and symptoms of blood clots such as swelling, redness, warmth, or pain in the affected limb. Choices B, C, and D are incorrect because tamoxifen is not associated with an increased risk of hot flashes, cataracts, or bone fractures.
4. What function does aldosterone serve in the body?
- A. Aldosterone causes a release of sodium from the body, decreases fluid volume, and decreases blood pressure
- B. Aldosterone causes a retention of sodium in the body, increases fluid volume, and increases blood pressure
- C. Aldosterone causes a release of sodium from the body, increases fluid volume, and decreases blood pressure
- D. Aldosterone enhances intracellular sodium production and lowers blood pressure
Correct answer: B
Rationale: Aldosterone functions by causing the retention of sodium in the body, which results in an increase in fluid volume and blood pressure. Choice A is incorrect because aldosterone actually promotes sodium retention rather than release. Choice C is incorrect as it states that aldosterone decreases fluid volume, which is not accurate. Choice D is incorrect because aldosterone does not enhance intracellular sodium production; instead, it primarily acts on sodium reabsorption in the kidneys.
5. A patient has been prescribed clomiphene citrate (Clomid) for infertility. What should the nurse include in the teaching plan about the use of this medication?
- A. Clomiphene is taken daily for 5 days at the beginning of the menstrual cycle.
- B. Clomiphene is taken once daily throughout the menstrual cycle.
- C. Clomiphene is taken twice daily for 5 days at the end of the menstrual cycle.
- D. Clomiphene is taken three times daily for 10 days at the beginning of the menstrual cycle.
Correct answer: A
Rationale: Corrected Rationale: Clomiphene is typically taken daily for 5 days at the beginning of the menstrual cycle to stimulate ovulation. Choice A is the correct answer because it aligns with the standard dosing regimen for clomiphene citrate. Choices B, C, and D provide incorrect information about the dosing schedule for clomiphene, which can lead to ineffective treatment and potential side effects. Choice B suggests continuous daily intake, which is not the standard practice for clomiphene. Choice C and D mention different dosing frequencies and timings, which are not in line with the typical protocol for using clomiphene for infertility.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access